GSK CEO Emma Walmsley Says Drugmaker Is ‘Betting Big’ on the US

GSK Plc is “betting big on the US” and engaged in constructive talks on drug pricing with US President Donald Trump’s administration, according to Emma Walmsley, the outgoing chief executive officer of the British drugmaker.

The US market is hugely important for all drugmakers and news on Tuesday that rival Pfizer Inc. has struck a medicines pricing deal with the Trump administration is a “step forward and it’s progress,” she said, speaking at Bloomberg’s Women, Money & Power conference.